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ABSTRACT
THERAPEUTIC TARGETING OF TUMOR ASSOCIATED MACROPHAGES
Stephanie K. Watkins
September 20, 2007

Previous studies on the mechanistic induction of anti-tumor responses by IL-12
cytokine therapy have focused on the adaptive immune response, specifically the
activation NK cells and T cells as the primary targets of IL-12 treatment. In contrast,
little attention has been given to the potential role of macrophages in the initiation of antitumor responses by IL-12 therapy despite reports that macrophages playa major role in
promoting tumor growth and metastasis and in suppressing anti-tumor immune responses.
Based on the functional adaptivity hypothesis, which is the concept that macrophages
functionally adapt, rather than differentiate into specific mature subsets, in response to
environmental stimuli, we hypothesized that tumor infiltrating (TIMs) as well as tumorassociated macrophages (TAMs) could be converted from tumor supportive activities to
pro-immunogenic activities by IL-12 therapy. We examined the functional activities
displayed by TIMs and TAMs after treatment with IL-12. Our data demonstrate (1) that
tumor cells and tumor exosomes activate TIMs and TAMs by c:ell-contact dependent
mechanisms involving ligation of CD40 and/or NKG2D, (2) that IL-12 treatment both in
vivo and in vitro induces a rapid reduction of tumor supportive: activities and a
concomitant increase in pro-inflammatory activities in TIMs as well as TAMs, (3) that
VI

IL-12 induces a rapid release of cytoplasmic IL-I5 from the in situ activated tumor
associated macrophages and (4) the release of IL-I5 in essential to the recruitment of
lymphocytes to the tumor and the metastatic lung, and to the destruction of the tumor and
clearance of metastasis. It is concluded that macrophages in the tumor environment are
activated and functionally modulated by the tumor. TIMs and TAMs respond to IL-12
treatment by rapidly converting from suppressive, tumor supportive activities to
inflammatory, pro-immunogenic activities. Tumor associated macrophages thus are a
critical target of IL-12 therapy and may orchestrate the subsequent NK and T cell
cytotoxic response against the tumor.
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INTRODUCTION

Macrophage Activation and Plasticity

Macrophages are important components of both innate and acquired immunity.
They are highly heterogeneous, and have the ability to take on many phenotypes and
functional properties. Macrophages are derived from circulating monocytes and either
remain motile or take residence within tissues in the host where they exhibit tissue
specific morphologies and distinct functional activities crucial for homeostasis of the
tissue. Many of the behaviors that macrophages display could be considered opposing in
nature, for example they can participate in pro-inflammatory or anti-inflammatory
activities, be tissue destructive or tissue restorative and immunogenic or tolerigenic (Fig.
1)1, 2. Each of these diverse activities can be triggered by a variety of response modifiers
such as cytokines, growth factors, hormones, arachidonates, stress hormones, PPARS,
FABPs, etc. as well as by an activation signal received, such as TLR, CD40 and/or TNFR ligation 1-5.
Macrophage activation traditionally refers to what is termed classical activation,
or the pro-inflammatory, and phagocytic functions that macrophages employ during antimicrobial immune responses. Macrophages are among the first cells to arrive at sites of
infection. Infiltrating monocytes respond to tissue cytokines and chemokines to up
regulate inflammatory activities. Upon activation macrophages increase expression of -1
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Figure 1. Macrophages are capable of many functions, many seeming opposing in nature,
anti-inflammatory vs pro-inflammatory, and toxic vs healing. The function displayed is
dependent upon the response modifiers encountered. Furthermore, macrophages will
continue to differentially and reversibly adapt the functional profile displayed in response
to progressive changes in the cytokine environment.
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CD40 and TNF receptors, elevate production of pro-inflammatory cytokines, TNFu, IL
and IL-6, and chemokines which recruit other immunological cells to the area. As the
response progresses macrophages produce increased INOS and NO, participate in
oxidative bursts and provide co-stimulation by the up-regulation of B7 and MHC class II
molecules

1,3.

At this point in the response, NK and T cells are present and producing

IFNy. IFNy promotes the "generation" of the activated macrophage which is referred to
as "classically activated" and displays enhanced pro-inflammatory and cytotoxic
activities.
In apparent opposition to the classically activated, pro-inflammatory functions,
macrophages are also among the first cells to arrive at areas of non-infectious wounding,
such as a muscle tear for example. In this situation, along with tissue macrophages they
promote wound healing and tissue repair by the production of growth factors, proteases
and angiogenic factors 3-5. Macrophages displaying wound healing or anti-inflammatory
type profiles are described as being "alternatively activated." Alternative activation was
first described by Siamon Gordon as macrophages activated in the presence ofIL-4 or IL13

3.

Others have extended this description to refer to macrophages which display any

pattern of function distinctly different from classically activated macrophages, and are
found to produce anti-inflammatory cytokines, such as IL-I 0 and TGFp, as well as having
increased arginase production 4-7.
Many have tried to classify macrophages into distinct populations characterized
by the state of activation or functional profile observed, for example classically or
alternatively activated or based on the cytokines involved in the activation, Ml for
cytokines typically involved in Thl responses and M2 for cytokines involved in Th2
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responses 5,7-10_ However, it is far too simplistic to suggest that macrophages are only
classically (MI) or alternatively activated (M2) or exist in a polarized state between the
two functional subsets. Macrophage activation is much more complex and can not be
described in a linear fashion. Efficient macrophage activation requires at least two
signals. One signal being a functional modulating signal, such as a cytokine, chemokine,
hormone, etc. and the second being a stimulating signal such as TLR and/or CD40
ligation or a mixture of cytokines

1,11.

One example of macrophage plasticity can be

observed by looking at a typical response to microbial infection. Once the bacteria have
been cleared, macrophages begin to phagocytose apoptotic neutrophils and down regulate
production of pro-inflammatory cytokines in favor of an up-regulation of tissue
restorative functions

12-14.

This situation provides a clear example of functional

adaptivity rather than subset replacement. A second example presented by our lab
demonstrates that upon activation the functional pattern displayed by macrophages
depends on the nature of the stimulating ligand, the modulating stimulus encountered and
the time points between when each signal was received and at what time point after
activation or modulation the function was assayed

1_

When bone marrow derived

macrophages were treated with IFNy for 24 hrs prior to LPS stimulation one pattern of
function was observed, showing increased TNFu, IL-lP, and IL-12 production and
decreased IL-l 0 and MCP-l production in comparision to bone marrow derived
macrophages stimulated with LPS alone_ A second pattern of function that was distinctly
different was then observed when the macrophages were treated with IL-4 instead of IFNy
for 24 hrs prior to LPS stimulation, displaying increased TNFu, MCP-l, IL-12 and IL-6
and decreased production oflL-l o. Additonally, other cytokine treatments prior to LPS
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continued to give different patterns of functions than observed from either IFN or IL-4
treatment. In demonstration that timing of stimulation is important, different patterns of
function were also observed when cytokine treatment (IFN, IL-4, etc.) and LPS
stimulation was administered simultaneously.

Moreover, we demonstrated that the

pattern of function displayed continued to adapt with progressive changes to the cytokine
environment 2, 11. These data established the functional adaptivity hypothesis, which
states that macrophages are not subsets of stably differentiated cells, but rather they are
plastic in nature and respond rapidly by changing their functional profile repeatedly as the
response modifiers within the environment sequentially change 2, 11.

Tumor Associated Macropbages

The functional adaptivity hypothesis is applicable to many disease states which
affect macrophage activation and functional profiles. One of the best examples of this is
macrophage function and support of cancer. Macrophages have been observed to be
associated with cancer for decades. However, their role in supporting tumor development
has been largely unappreciated. Only recently have the observations that macrophage
densities impact clinical outcomes become respected.
Cancer progression and/or tumor development is highly dependent on the tumor
cell's ability to interact with its surrounding stroma. Tumor stroma content can vary from
model to model, however, most are found to contain high numbers of fibroblast,
endothelial cells, and possibly most importantly, macrophages 6. High densities of tumor
associated macrophages (TAMs) are reported to indicate a poor prognosis, specifically in
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models of breast, prostate, ovarian, and cervical cancers

15,16,17,18.

Many studies have

shown that macrophages are critical to tumor progression 6, 15, 19-24. In one example, Lin
et al. have shown that depletion of macrophages in breast carcinoma delayed tumor
progression and reduced metastasis 25,26. In another study, Nowicki et al. reported
impaired tumor growth in CSF-I deficient mice, which are macrophage deficient, as
CSF-I is required for differentiation ofmonocytes

16,27.

The roles that macrophages play

in tumor development are highly dependent on the tumor micro-environment

15,28.

Tumors have been shown to actively recruit macrophages by the production of an array of
chemokines and growth factors, most notably MCP-I and CSF-I

6,29,30.

Tumors then

seem to co-opt the normal role of macrophages to promote their development, invasion,
and angiogenesis. Logically, macrophage recruitment to tumors should be
immunologically beneficial to the rejection of the growing tumor. The tumor would be
recognized as foreign due to tumor associated antigens (TAA) and normal macrophages
would initiate an anti-tumor response, presenting TAA to T cells. However, the tumor
micro environment is highly immuno-suppressive, therefore TAA are not being
recognized and macrophage functions are being modulated toward pro-tumorigenic and
immuno-suppressive functions by anti-inflammatory tumor produced metabolites, such as
TGF~,

VEGF, MMPs, and PGE2 (Fig. 2)

11,28,31-34.

Of the many pro-tumorigenic functions that TAMs display, angiogenesis is one of
the most important for tumor growth 35,36. Tumors require angiogenesis to grow beyond a
certain size. Pollard has reported TAMs are responsible for "throwing the angiogenic
switch" 15. TAMs contribute to angiogenesis by the production of essential factors, such
as IL-I, TNFa, IL-8, MMP-9 and VEGF. How TAMs initiate angiogenesis is poorly
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Figure 2. Macrophages which would otherwise be capable of promoting tumor
destruction and cytotoxicity are influenced by metabolites of the tumor microenvironment to promote tumor growth. Tumor growth is supported by macrophage
production of cytokines and growth factors, which aid in angiogenesis, tumor migration,
and immunosuppression.
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understood. However, TAMs have been observed to cluster in areas of hypoxia.
Hypoxia up-regulates the transcription factor, hypoxia-inducible factor 2-a (HIF-2a) in
macrophages, which in tum induces VEGF expression. VEGF expression can then up
regulate eSF-I, as well as act as a chemoattractant for further macrophage recruitment 25,
35,36.

Other molecules influencing angiogenesis include the production ofIL-I and

increased eOX-2, both of which further increase HIF-Ia, inducing transcription ofVEGF
26,37.

MMPs, especially MMP -9 which is essential for the cleavage of biologically active

VEGF, have also been shown to be up-regulated. According to reports studying tumor
angiogenesis VEGF and MMPs are the most critical to vessel formation 26,37,38.
Production of these factors, along with cytokine production of IL-I, IL-8, and TNFa,
results in the proliferation and migration of endothelial cells, matrix remodeling, and the
formation of blood vessels

15,35,39,40.

In addition to angiogenic roles, TAMs are essential in other areas of tumor
development as well, including metastasis, and immunosuppression. In metastatic
development, macrophages infiltrate the basement membrane. This invasion along with
the production of proteases degrade the basement-membrane which creates a portal
through which tumor cells can enter the stroma 31,36. The tumor cells are recruited to the
portal by macrophage production of growth factors which serve as chemotactic molecules
allowing tumor migration and metastatic spread

17,31.

In immunosuppression, several populations of "suppressor" macrophages have
been described. The first set described by Bordin in 1976, and further characterized by
Mantovani, referred to TAMs which are recruited from circulating blood monocytes and
are believed to be mature macrophages that have been polarized by tumor products. No

-8-

distinct phenotype has been described for this population, however they are known to
produce cytokines and growth factors favorable to tumor growth such as those previously
mentioned 5,41.

The second population described by Bronte and Gabriolovich is referred

to as an immature myeloid suppressor (ImC) cell with a phenotype CD 11 b+IGRI +ICD31 +.
They have been described to be able to "mature" to either a type I or type II polarized
functional state depending on the cytokine treatment. However, this population has only
been described in the tumor in the late stages of development, typically accumulating in
the spleen and other lymph tissue 27,42-45. Gabriolovich reports that the ImC impair
alloreactivity in vitro through a nitric oxide dependent mechanism and induces T cell
apoptosis but require cell-cell contact 45,46. The third population is described as a mature
myeloid cell by Rodriguez that accounts for high arginase I production and has a
CDIIb+/GR-I" phenotype, but are also CDI6+ICD32+ and I-A/l-E+. Though the

mechanisms are poorly understood, no cell-cell contact seems to be required for the
inhibition of T cell activity by this popUlation. This population of TAMs are reported to
display distinct morphology consisting of irregular cytoplasms with high intracytoplasmic vacuoles and are low in phagocytic nature which makes their functional
pattern unique from the other TAM populations reported 47. To date there has been no
relationship described for between these three individually described populations, nor has
there been a study addressing, at which time point during tumor development the
different functional patterns are displayed by the TAMs. TAM function is known to vary
based on the locations within or around the tumor, such as within perivascular sites,
stromal regions, and hypoxic or necrotic areas, as well as in the metastatic tissue 35,36.
Application of the functional adaptivity hypothesis may explain some of the discrepancies
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in deciphering these seemingly different TAM populations or TAMs functional profiles.
The pattern of function displayed is influenced by the cytokines and growth factor
components within the tissue micro environment. The levels of these metabolites change
during tumor development and in different tumor micro environments (peri-vascular vs
tumor parenchymal), these progressive changes would in turn cause the functional
profiles of TAMs continue to shift.

TAM activation

All of the functional profiles that have been observed indicate that TAMs are
actively producing cytokines, chemokines, and growth factors and contributing to tumor
growth, suggesting that they are in some way activated. While it is known that tumor
produced growth factors contribute to the continued modulation of TAM function 31,32,33,
48,

how TAMs actually become activated to elicit pro-tumorigenic functions remains to

be determined. Some speculation includes activation by recognition of tumor associated
antigens (TAA) or by the mixture of cytokines present with the tumor, but these
speculations do not explain the activation of TAMs residing in tissues distal to the
primary tumor mass. There are reports of tumor suppression mediated by the release of
membrane vesicles or exosomes. Exosomes were first described in 1987 by Johnston
while studying reticulocytes from sheep 49. Exosomes are formed by the inward budding
of endosomal membranes, which are then referred to as multivesicular bodies, then are
then secreted from endocytic compartments after fusing with the plasma membrane 50,51.
Many cells have been shown to release exosomes including APes, epithelial cells, mast
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cells, and tumor cells. Exosomes are believed to function in two ways, first they are
thought to eliminate obsolete proteins during cell maturation and secondly, they have
been reported to communicate among cells by cell contact, participating in immune
stimulation and immune suppression 52. Similarly, exosomes circulating in the tumor
bearing host would interact with cells of the immune system allowing for both activation
and suppression. NK cells, for example have been reported to be suppressed by
interaction with the over-expression ofNKG2D ligands on the surface of tumor cells and
tumor released exosomes 20,53,54. Further investigations of suppression reveal that tumor
exosomes mediate CD8+ T cell apoptosis by Fas ligand 55. Stimulation by exosomes has
been evidenced by the ability of DC derived exosomes to be able to effectively activate T
cells in the absence of viable APCs 52. An exosome expresses the same receptors and
ligands as the area of the cell membrane from which it was generated. Tumor cells
express many surface molecules important in both suppression of cells of the immune
system and for stimulation of tumor cell proliferation. Among the molecules reported are
corresponding receptors and ligands which could theoretically allow for self stimulation
such as, CD40/CD 154 and NKG2DlRae-1

20,53,56.

Many other cells of the immune

system also express these receptors or ligands, which provide them with activation
signals. Macrophages express CD40 and be can efficiently activated by the ligation of
CD40 by CD 154

12,57.

It has not been examined as to whether tumor exosomes interact

with tissue macrophages, which may provide some insight as to how macrophages distal
to the tumor mass become activated TAMs and are induced to express pro-tumorigenic,
pro-metastatic and anti-inflammatory activities.

-11-

TAM Plasticity and Cytokine Therapies.

There is evidence that TAMs are not a stable subset of pro-tumorigenic immunosuppressive cells, but rather their functional profile can change. Chu et al, have derived
DCs from TAMs with IL-4 and GMCSF treatments and compared their ability to present
Ag with DCs that were derived from peripheral blood monocytes of a healthy mouse. It
was observed that DCs presenting TAA were capable of stimulating IFNy secretion by
tumor specific T cells at the same level as, or in some cases higher levels than the
peripheral blood monocyte derived DCs 58. Another example generated in our lab,
showed that TAMs respond to IFNy treatment in vitro by reducing production of protumorigenic cytokines, MCP-l and IL-IO and increasing pro-inflammatory, TNFa and IL-

6 production in comparison to normal macrophages upon LPS stimulation II. These
examples indicate that TAMs maintain functional plasticity and are capable of adapting
their cytokine profiles in response to changes in environmental signals and/or stimulation.

It is well established that tumor produces and inflicts its anti-inflammatory products on
macrophages encouraging them to aid in tumor growth

15.

However, observing TAM

function after interrupting the tumor environmental signals, in other words testing their
adaptivity, such as through cytokine treatments has not been examined.
Cytokine therapies have previously focused on NK, NKT, and T cell responses
59-61

13,

Much of the success has come from the administration of pro-inflammatory

cytokines, such as IL-12 and or IL-2IIL-12. IL-12 is a heterodimeric molecule made up of
an a chain, the p35 subunit, and a t~ chain, the p40 subunit. The subunits are linked by a
disulfide bridge, which forms the biologically active heterodimer
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14,62.

IL-12 plays an

essential role in interactions between the innate and adaptive responses. It is produced by
macrophages, DCs, B cells, and possibly other accessory cells

14,62.

IL-12 activates T

cell and NK cells proliferation and production of IF Ny. IL-12 was fIrst shown to induce
anti-tumor effects by Brunda et. al.

13.

They reported that the potent anti-tumor effects

were based on the induction ofIFNy and the activation ofNK and CD8+ T cells

13,14,63,64.

Since then there have been many studies further supporting IL-12 anti-tumor activity in
various tumor models, including melanomas, colon cancers, and mammary carcinomas 60,
65.

In addition to effector cell activation IL-12 has been shown to possess potent anti-

angiogenic capabilities and can inhibit growth factor production. Even in light of the
many beneficial anti-tumor effects ofIL-12, there have been severe difficulties with
clinical trials due to considerable toxicity when administered systemically. Hill and
Egilmez, as well as many others have developed methods of administration to overcome
clinical toxicity by encapSUlating IL-12 in lipid micro spheres or nanovessicals, alone or
with other cytokines such as IL-2 and GMCSF in the treatment regime 23,61,66,67. This
method allows for both local delivery as well as for a slow release of the cytokines,
enabling the initiation of an effective response, while minimizing side effects and toxicity
61,66.

Hill et al. showed significant results in that IL-12 and GMCSF delivered in

microspheres greatly reduced tumor proliferation, metastasis, and recurrence, and
ultimately enhancing survival by 60% 61. The study showed that the anti-tumor effect
was IFNy mediated and required a NK and NKT cell response as well as a long term,
tumor specific adaptive T cell response 23,61,66. Trinchieri et al. confirmed the findings
of Hill, and showed that the effectiveness of IL-12 therapy is IFNy mediated through the
induction of CXC chemokines, such as IP-I 0 and MIG 60,68.
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Other pro-inflammatory cytokines, such as IL-18 and most impressively IL-15
have been reported to act synergistically with IL-12, further enhancing anti-tumor
responses 69,70. IL-15 was identified by its structural and physiological similarities to IL2 and by its ability to stimulate proliferation ofthe IL-2 dependent CTLL-2 T cell line in
the presence of neutralizing Abs to IL-2 2,71. Much is still unknown of the synthesis and
release ofIL-15, however, it is known to activate through one or a combination of its
receptors, IL-15Ra,p,or y in soluble or, most often, a membrane bound form 71,72. IL-15 is
produced by many cell types including skeletal muscle, BM stromal cells, thymic
epithelia, heart, lung, and monocytes and macrophages. Monocytes and macrophages
were the first cell types to be reported as a functionally relevant source of IL-15 in the
context of the immune response 71. IL-15 has an essential role in the development and
activation of many immune cells 73-75. IL-15 is required for NK cell development as is
demonstrated by the absence ofNK cells in mice deficient in IL-15, IL-15R, and/or in the
JAK3 and STA T5 signaling pathways, which are required for IL-15 production or

signaling by IL-15R 76,77. Furthermore, IL-15 is essential for NK proliferation,
cytotoxicity, and cytokine production, as well as for NKimacrophage interactions 71,72,78.

In addition to NK cells IL-15 is also essential to chemotaxis, proliferation, production of
cytokines, protection from apoptosis and for cytotoxicity in T cells 79-81. Again, mice
deficient in IL-15 or IL-15R lack functional CD8+ T cells and have minimal reactive
CD4+ T cells 75,81,82. In the context of cancer, it was recently discovered that IL-15 could
rescue tumor suppressed CD8+ T cells, allowing for enhanced survival 79,81,83,84.

This

revelation may be a key in understanding the mechanisms by which cytokine therapies
may be improved to be more effective.
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Hypothesis, Significance, and Summary.

To date, all studies regarding cytokine therapies have focused on the adaptive
anti-tumor response generated 6 or more days after treatment 61,85,86. However, the initial
events from hours to several days following treatment have been ignored. The early
events of cytokine therapy are likely to induce the production and/or release of other
cytokines, such as IL-18 and/or IL-15 which would act synergistically with the
administered cytokine in promoting the later observed adaptive response. It is unlikely
that the potent adaptive anti-tumor response could take place without first reducing the
highly immuno-suppressive influence of the tumor environment. In realization of this
some studies have tried to circumvent the suppressive tumor environment by surgically
removing the primary tumor mass prior to administering cytokine treatment 61.
While the effects of removing the primary tumor mass would be beneficial, we
hypothesize that the disruption of the apparent tumor, macrophage relationship may
provide the needed window of opportunity for the activation and promotion of the
adaptive anti-tumor response. Although, macrophages are not activated by IL-12, they
are responsive in so far as their functional profile is modulated by JL-12. Given the
elevated production of pro-tumorigenic cytokines and growth factors observed to be
produced in the tumor bearing host, we furthermore hypothesize that TAMs are activated
in a tumor-supportive fashion in situ, but will adapt their function to a more proimmunogenic profile in response to IL-12 treatment (Fig.3).
In this study, macrophage activation by NK interactions, as well as by soluble
tumor produced molecules, tumor cells and tumor exosome interactions were examined,
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before and after IL-12 treatment. Macrophages were observed to be activated by cell-cell
contact with tumor cells and/or tumor exosomes, which was prevented by the blockade of
either CD40 or NKG2D ligation. Activated TAMs rapidly responded to IL-12 treatment
by increasing pro-inflammatory cytokine production and releasing their intracellular store
ofIL-15. The release ofIL-15 was observed to mediate infiltration ofCD4+ and CD8+ T
cells into the tumor mass and metastatic lung. Furthermore, IL-15 release and
lymphocyte infiltration coincided with tumor destruction and metastatic clearance. The
observations made in this study provide insight as to the tumor/TAM relationship and on
the impact of IL-12 treatment in the adaptation of the TAM functional profile in vitro and
in vivo, which may contribute to the promotion of the anti-tumor response and ultimately
destruction of the tumor and/or metastases.
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work synergistically with the IL-12 treatment to rescue and activate tumor suppressed
NK, NKT cells and to promote the expansion and survival of CD8+ T cells. The
motivated cells and enhanced effector functions promote cytotoxicity and tumor
destruction.
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MATERIALS AND METHODS

Animals. C57Bl/6J, C57B1I6J _CD40tmIKiklJ, C57B1I6J-Lystbg-T, and DBAJ2J female mice
were obtained from Jackson Laboratories. C57BLl6J-IL-15KO mice were obtained from
Taconic Farms. All animal protocols received prior approval of the Institutional Animal
Care and Use Committee and all experiments were performed in accordance with relevant
guidelines and regulations.

Tumor models. Lewis Lung carcinoma (3LLC) transfected to express membrane human
Muc-l was obtained from Dr. Gordon Ross, Brown Cancer Center, Louisville, KY. TC-l,
B16Fl, and LL-2 tumor lines were purchased from ATCC. Tumors were maintained by
in vivo passage with limited intermittent culture in vitro. Tumor cells were injected s.c.
in the left side of C57BLl6J mice. Tumors were measured at 3 day intervals with calipers
at two bisecting diameters and an approximate volume is calculated by the formula (0.4)
x (large diameter) x (small diameterf . Tumors were excised at 0.4-0.6 cc, diced and
passed through a sieve (Bellco, Vineland NJ). The cells were washed with Dulbecco's
PBS + 2% FBS and cultured for 2-:5 3 day cycles in RPMI1640 with 5% FBS, HEPES,
and gentamycin before re-passage in vivo. Tumors with necrosis or with volumes
twofold higher or lower than the mean of the group of mice were not used as a source of
tissue for that experiment.
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Macrophages. Macrophages were purified from single cell suspensions of lung, spleen,
peritoneal lavage, and tumor mass of tumor bearing animals by magnetic bead separation
using first a negative selection with anti-CDl9 and anti-CD5 and then positive selection
with anti-CDllb (Mac-I) (Miltenyi Biotech, Auburn CA).

The lungs and tumors were

excised after perfusion with PBS-EDTA and removal ofthe mediastinal lymph nodes.
Samples were treated with collagenase and DNase (Sigma) in 37° water bath for 30 min.
Dispersed cells were then centrifuged over a discontinuous 30/35/45/70% percoll
gradient. Macrophages were purified by magnetic bead separation from the cells banding
at the 45/70% interface. Purity of>95% CDl1b+ 1F480 was confirmed by flow
cytometry for all 4 macrophage populations. Macrophages were cultured in RPMI1640
supplemented with 5% fetal calf serum, HEPES, and gentamycin and were activated by
addition of 100 ng/ml LPS where indicated.

NK cell isolation. NK cells were purified from single cell suspensions of the spleen from
normal animals by magnetic bead selection using the DX5 magnetic beads and columns
from Miltenyi Biotech.

Exosomes. Tumor exosomes were purified by magnetic bead selection. Tumor
supernatants from cultures of adherent tumor cells were collected and centrifuged at 1500
rpm for 10 min. to remove any detached intact tumor cells. 4p.g of biotinylated antiBCP8 (MUC-l) was added to 5ml of tumor supernatant for 15 minutes at room
temperature. Anti-biotin magnetic beads (Miltenyi Biotech) were then added to the
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supernatant for an additional 15 minutes at room temperature. Exosomes were then
positively selected for using Macs columns (Miltenyi Biotech, Auburn CA).

In vitro Cytokine treatment. Macrophages were plated at 1x105/ml in a 96 well plate
for cytokine analysis or a 6 well plate for flow cytometric analysis. rm-IFNy was added to
cultures at 20 ulml and soluble rm-IL-12 was added to cultures at 5 ng/ml. Cultures were
incubated from 17- 48 hrs as indicated.

In vivo IL-12 treatment. Interleukin-I2 containing micro spheres were prepared by
phase inversion nanoencapsulation and supplied by Dr. Nejat Egilmez, State University,
Buffalo NY 61,66,67. Microspheres were re-suspended at Img/IOOj.l1 in PBS for injection
into the center of the tumor mass.

Flow Cytometry. Cells were treated at Ij.lg/106 cells with Fc block (Pharmingen) for 15
minutes in the presence of 0.1 % azide and 3% heat-inactivated fetal bovine serum
(staining buffer). The cells were then incubated with fluorochrome conjugated antibodies
at appropriate dilutions in staining buffer for 30 minutes on ice, washed and analyzed on
a B-D FacsCalibur. Typically 10,000-20,000 cells were analyzed for their expression of
surface proteins. Antibodies reactive with MAC-I, CD40, CDI54, CD44, H2Kb, Gr-1,
F480, CD69, CD45, CD8, CD4, CD3, IL-I5RJ3, and NK1.1 were purchased from BD
Pharmingen, anti-CD3I4 (NKG2D/CX5) was purchased from Biolegend, anti-hMuc-l
(BCP8) provided by JUll Yan, Brown Cancer Center, Louisville, KY, and pan-specific
anti-Rae-1 was purchased from R&D Systems. Intracellular IL-15 was assayed using the
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BD Pharmingen cytofix/cytoperm kit per manufacturer's instruction along with the
biotinylated goat anti-mouse IgG IL-15 antibody (R&D Systems) with a secondary
streptavadin Ab (BD Pharmingen). Un-labeled anti-IL-15 (Novus Biochemicals) was
used as an Ab control for intracellular staining. Appropriate isotype controls were ran for
each Ab used.

SuperArrray. For the GEArray cells were purified and lysed in Trizol for a cholorform
extraction. Briefly 200~1 of choloroform was added to celllysates and centrifuged. The
aqueous phase was collected and an equal amount of(25:24:1) phenol: choloroform:
isoamyl alcohol was added and centrifuged. The aqueous phase was collected and
washed with isopropanol, centrifuged and was with ice-cold 75% ethanol. After
centrifugation the pellet was air dried, then resuspended in nuclease-free water for further
purification by Qiagen Mini Elute RNA easy clean-up kit according to the manufacturer's
instructions. The GEArray was then run according to manufacturer's instructions using
3~g

purified RNA. Data was analyzed by software provided by SuperArray for the

GEArray Q series kit (software available on SuperArray website www.Superarray.com).

Quantitative Real Time peR. cDNA was produced from mRNA from 106 cells from
independent cell culture experiments (in treated and untreated tumor bearing and normal
mice) by using t-LMACSTM One-Step cDNA kit (Miltenyi Biotec). The cDNA was used
for quantitative real-time polymerase chain reaction (PCR) amplification with Sybr Green
using gene specific primers for MIF (Superarray), TGF~, IL-15, and IL-18 (Maxim), and
Klrk-1 (NKG2D) (Qiagen). Duplicate cDNA template samples were amplified and
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analyzed in the MJ Opticon thermal cycler with conditions of 96°C for 15 min followed
by 40 cycles of 95°C for 30 sec, 58°C for 30 s and 30 s at 72 with a plate read for gene
expression between each cycle. A standard curve of cycle thresholds using 10 fold serial
dilutions of cDNA samples was established and used to calculate the relative abundance
of the target gene of each cytokine and vehicle control samples. Samples were run
according to manufactures protocol and analyzed as fold increases or decreases between
normal and tumor bearing animals after normalization to a J3-actin control. Differences
between groups were analyzed using the REST program.

Cytokine Analysis. Cytokines were assayed using Becton-Dickinson's cytokine bead
array kit and a BD FacsCalibur according to manufacturer's instructions. Sample
supernatants were analyzed undiluted and also at a 1:50 dilution. ELISAs for TGFb,
VEGF, and MMP-9 were performed using the Quantikine kits from R&D Systems, as per
manufacture's instructions. The IL-15 ELISA was performed using rat anti-mouse IgG2a
IL-15 Ab (R&D Systems) at 4mg/ml as the capture Ab in combination with the
biotinylated goat anti-mouse IgG IL-15 antibody (R&D Systems) at 400 ng/ml as the
detection Ab.

Blocking Abs for in vivo studies. Neutralizing anti-IL-15 and IgG isotype control was
obtained from eBioscience. Anti-IL-15 or the isotype control was injected i.p. At 500 ng
1 hr prior to intra-tumor IL-12 microsphere treatment. Anti-NKI.l was obtained from
BD Pharrningen and injected at 250 ng 24 hrs prior to IL-12 microsphere treatment.

-22-

Blocking Abs for in vitro studies. Anti-NKG2D (R&D Systems) was added to
macrophages in vitro at 2~g/ml,

5~g/ml,

or

lO~g/ml

to block NKG2D ligation. To

measure specificity ofthe blocking anti-NKG2D, Fc-rmNKG2D purchased from R&D
systems was added to cultures at 1,2,5, or 10 ~m1ml. Anti-CD154 (Biolegend) was
added to 3LLC cells and exosomes with and without macrophages in vitro at 5~g/ml,
lO~g/ml,

or 25~g/ml to block the tumor cell ligation of macrophage CD40.

Infiltration Studies. Mice were injected with 3LLC tumor cells subcutaneously, when
the tumor measured O.5cc anti-IL-15 or anti-NK1.1 were injected 1 hr and 24 hrs prior to
IL-12 microsphere injection respectively. Three and 5 days post treatment tissues were
harvested. Mice were purfused with 10ml cold PBS, and the tumor mass and lungs were
removed. Tumor diameter was recorded as previously mentioned. Wet weights ofthe
tumor were recorded and digital images were obtained. The tissues were then pressed
between frosted slides to acquire single cell suspensions. Cell populations were then
stained for flow cytometric analysis.

Histology. Animals bearing tumors were purfused with 10 ml PBS prior to lung
extraction. The lungs were then harvested and kept in individual cassettes which were
placed in 10% buffered formalin for 16 hours, washed in 70% EtOH and taken to
University of Louisville School of Medicine, Pathology Department, (Louisville KY) DJr
sectioning and H&E staining.
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Digital Images. Digital images of the slides obtained from pathology services were taken
with a Nikon coolpix digital camera at lOx magnification on a microscope. Slides were
also scanned on a HP scanner unmagnified to count visible metastatic nodes.

Statistical analysis. For flow cytometric analysis of the neutralization of IL-15 or
depletion ofNK cell studies, the mean and standard deviation was calculated on the
number of infiltrating CD4+/CD45+ and CD8+/CD45+ cells per lx106 tumor cells or
lx106 viable lung cells recorded from 5 mice or 3 mice respectively. The significance
between groups (5 individual mice/group) for cytokine production assayed by ELISA,
CBA, or qrt-PCR, and tumor volumes and masses were determined by the two sample t
test.
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RESULTS

Tumor associated macrophages display an anti-inflammatory CDllb+/Gr-l+
phenotype that shifts in response to inflammatory cytokine treatment.

An accwnulation of myeloid or macrophage suppressor cells have been observed
in many tissues of twnor bearing hosts. The cells are characterized by a CD 11 b +/Gr-l +
phenotype and are thought to be contribute significantly to the suppression of the immune
response by the production of anti-inflammatory or pro-twnorigenic cytokines. Primarily
these cells have been reported to originate from the bone marrow and infiltrate tissues
such as the spleen, liver, and lung and aid in metastatic development as well as immune
suppression

19, 35, 43, 87.

To determine whether resident macrophages from the peritonewn

of tumor burdened animals displayed the anti-inflammatory, "suppressor" phenotype,
macrophages were purified from twnor-bearing or healthy mice. The cells were then
stained with anti-CDllb and anti-Gr-l (LY6G/C) fluorescent antibodies for flow
cytometry analysis. The surface phenotype of macrophages from the twnor bearing
animals display a shift from CD 11 bHi to CD 11 bLow in comparison to normal peritoneal
macrophages. Concurrent with the shift in CD 11 b expression, approximately half of the
CD 11 b+ TAM population also expressed the Gr-l + phenotype (Fig 4.). Similarly TAMs
purified from the spleen and lung of twnor mice also displayed an increase in Gr-l
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Figure 4. Tumor associated macrophages display the anti-inflammatory "suppressor"
phenotype similar to tumor infiltrating macrophages. Macrophages from tumor bearing
and normal mice were enriched from the a) peritoneum, b) spleen, and c) lungs and
stained for cell surface expression ofCDllb and Gr-l (Ly6G/C). Results are
representative of three independent trials.
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expression. Macrophages however, are known to have transient phenotypes and change
functions due to changes in the micro-environment 1,2, 11. Therefore to determine if the
phenotype of these macrophages was stable, TAMs were treated in vitro with proinflammatory cytokine IFNy (Fig. 5) for 24 hours. Subequent flow cytometric analysis
revealed that the Gr-I + expression receded and the CD 11 bHi phenotype was restored (Fig.

5)
In addition to their distinctive surface phenotype it has been reported and we have

confirmed that, TAMs produce elevated levels of pro-tumorigenic cytokines, such as
MCP-I and TGFp in response to LPS stimulation in comparison to normal macrophages
from the peritoneum. (Fig.6). Treatment overnight with IFNy prior to LPS stimulation
reduced pro-tumorigenic cytokines production (Fig.6)

IL-12 treatment in vitro alters the functional profile of TIMs and TAMs.

While IFNy treatment overnight is effective for altering macrophage function in
vitro, pro-inflammatory cytokines, such as IL-12 have been shown to induce an antitumor response with less toxicity when delivered locally to the tumor 61,66,67. To gain a
broader perspective of the differences in cytokine gene expression between normal
macrophages and TAMs and to define the impact of IL-I2 treatment, macrophages were
isolated from the peritoneal cavity of normal and tumor bearing mice and cultured
overnight with or without IL-12. SuperArray analysis indicated that many cytokine genes
were down-regulated in TAMs, most notably IFNy and TNFa, as well as several cytokine
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-29-

receptor and chemokine genes. Other genes such as, MIF, IL-I0 and CCR2, which are
products known to aid in tumor development were greatly up-regulated in TAMs
compared to normal macrophages (Fig. 7a). Overnight treatment with IL-I2 appeared to
enhance expression of the genes that were down-regulated in TAMs and simultaneously
reduced the expression of the genes that were up-regulated in TAMs (Fig. 7b). Based on
the results of this assay two pro-tumorigenic cytokines genes of interest, TGFp and MIF,
that were found to be significantly up-regulated by the presence of the tumor and a proinflammatory cytokine gene of interest, IL-I5 that were found to be up-regulated by IL12 treatment of TAMs by the superarray (Fig. 7b) were selected for quantitative analysis
by real time qrt-PCR. TAMs expmssed a greater than 9-fold increase in expression of
TGFp and MIF mRNA but very little IL-I5 or IL-I8 mRNA compared to normal
peritoneal macrophages (Fig.8). Overnight culture with IL-I2 reduced the expression of
both TGFp and MIF genes to near background levels and induced a 3-fold increase in
expression of IL-I8 mRNA and a 20-fold increase in expression of IL-I5 mRNA (Fig.8).
Given the vast differences in gene expression we then analyzed the pattern of
cytokine production elicited by activation in vitro, the tumor infiltrating (TIMs) and
peritoneal, splenic or lung TAMs were stimulated with 100ng/ml LPS immediately ex
vivo or after overnight culture with rIL-I2. IL-12 treatment reduced or abrogated MCP-I
production and elevated TNFa and IL-6 production by TIMs as well as by peritoneal,
splenic and lung TAMs (Fig.9). The IL-I2 treatment reduced IL-IO production by splenic
and lung TAMs (Fig. 9) but elevate:d IL-IO production by peritoneal TAMs (Fig.9).
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Therefore, for each tissue analyzed, IL-12 treatment altered the pattern of the cytokine
response to LPS stimulation.

IL-12 treatment in vivo alters the functional profile of TIMs and TAMs.

IL-12 effectively modified macrophage cytokine production in vitro, but to
determine if IL-12 could alter the function of TAMs in vivo, mice bearing subcutaneous
3LLC tumors were treated with IL-12 encapsulated microspheres. Peritoneal
macrophages were harvested from 90 min to 5 days post injection and assayed for
cytokine production following LPS stimulation. IL-12 treatment induced a dramatic shift
in cytokine production in the peritoneal TAMs as early as 90 minutes after treatment (Fig.
10). The elevated production of MCP-l and IL-I0 elicited from peritoneal TAMs from
the placebo-treated tumor-bearing mice was reduced 2-3 fold in TAMs from the IL-12
treated mice. Furthermore the production ofTNFa was observed to be elevated in TAMs
following IL-12 treatment. This shift in funetional profile was sustained for at least 5 days
after IL-12 treatment (Fig. 10). Purified IWlg and splenic TAMS (Fig. lla) displayed the
same shift in their functional profile as peritoneal TAMs after injection of the IL-12
microspheres. TAMs from spleen and lung displayed elevated production of MCP-l and
IL-I0 and decreased production of IL-6 relative to normal controls. Three hours after IL12 treatment, the splenic and lung TAMs displayed a 3-fold or greater reduction in MCP1 and IL-l 0 production in response to LPS stimulation in vitro and a comparable increase
in TNFa and IL-6 production (Fig. lla). Pmified TIMs from IL-12 treated mice displayed

-J3-

a. TIMs
TIMs +

I~~;r;~~~~h~*III-:_: ___---II~I~!"
o

200

400

600

800

1

pglml MCP-I

2

3

4

]. If~~~~]'::.'*~

(~

0.5

ngimlIt-IO

15 25

0

10

nglml TNFa

20

30

40

ngimlIL-6

b. Peritoneal M<lls

NormaI=~~~~iJa3
N~"+~:%'
"].
1.. = : J ' . J~ ~r
TAMs + IL-I2

'----------'
200 400 600 800 0

o

05

pg/ml MCP-1

10 20 30 0

nglml IL-IO

c. Splenic M<lls

N~:~I~.
~..
S

Normal + IL_12

TAMs + IL-12

0.5

I

5

15 25

0

20

10

nglml TNFa

30

40

nglmllL-6

59J"EJ"~.
EB" Ej*J..
J..

•

o

0.5
1
1.5
nglml MCP-I

2 0

d. Lung M<lls

Normal~.
~t~s

Normal +

TAMs + IL-12

1

2
3
nglmllL-IO

l~

4 0

2

4
6
nglml TNFa

8 0

2

4
6
nglmllL-6

8

~..
•

o

200

400

600 8000

pglml MCP-I

2

4

6

nglmllL-1O

8 0

2

4

6

8

nglml TNFa

10 0

1

2

3

4

5

ngimlIL-6

Figure 9. IL-12 changes the pattern of cytokine production by TIMs and TAMs in vitro in
response to LPS stimulation. Macrophages were purified from a) the tumor, b) peritoneal
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IL-12. The culture supernatants were collected and analyzed for cytokines by CBA. Data
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are representative of four independent trials.
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Results are representative of 4 independent trials.
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later for cytokine analysis. Data is displayed as mean ± s.d. of 3 mice per group.
*indicates p<O.OS. **indicates p<O.OI. n.d.

= none detected. Results are representative of

4 independent trials.
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enhanced IL-6 production and dramatically decreased MCP-I production as compared to
placebo (Fig. II b). Unlike TAMs, TIMs consistently failed to produce IL-I 0 in response
to LPS stimulation in these studies (Fig. 11 b). We attributed the differences observed in
cytokine production by TIMs and TAMs to differences in the tissue environments from
which they were purified.

IL-t2 induces release oflL-iS in tumor bearing mice.

Analysis of TAMs from the spleen, lung, and peritoneal cavity ex vivo for
cytokine gene expression corroborated previous reports that genes for MIF and TGFp
were significantly elevated (Fig.12a ) 5,33,36, 88, 89. Within 90 min after IL-12 treatment in
vivo, the splenic, lung, and peritoneal TAMs displayed almost a complete abrogation of
expression of MIF and TGFp mRNA. This sharp down-regulation of tumor-supportive
TGFp and MIF gene expression was accompanied by a greater than 10 fold increase in
expression of IL-15 and IL-18 mRNA relative to placebo (Fig.12b ). Therefore, the same
impact ofIL-12 on expression of these 4 cytokine genes by TAMs was observed both in
vitro (Fig. 8) and in vivo (Fig. 12a,b). IL-15 administration to tumor bearing mice has
been reported to rescue anergic/tolerant tumor-specific cytotoxic T cells. The dramatic
IL-12 mediated up regulation ofIL-15 gene expression (Fig. 12b) was therefore of
particular interest. To determine if IL-15 protein was being released as a result of IL-12
treatment, a blood sample was obtained from mice 2-24 h after IL-12 treatment. Analysis
revealed that 3 h after IL-12 treatment there was a rapid appearance of IL-15 in the serum
of tumor-bearing mice, attaining >6-fold higher concentration than that observed in
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Figure 12. IL-12 injection induces a decrease in pro-tumorigenic and an increase in proimmunogenic cytokine genes. Peritoneal, lung, and splenic macrophages were purified
from normal or tumor bearing mice 90 min after IL-12 injection. The cells were
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normal mice treated with IL-I2 (Fig. 13a). The contribution of TAMs to this IL-I5
release was investigated by collecting peritoneal macrophages before and after IL-I2
treatment and analyzing for the level of cytoplasmic IL-I5. IL-I2 treatment of normal
mice induced an increase in cytoplasmic IL-I5 in a small fraction of the macrophages
whereas IL-12 treatment of tumor bearing mice resulted in nearly a complete depletion of
cytoplasmic IL-I5 (Fig. I3b,c). IL-I5 appeared to be released rapidly as a bolus reaching
maximum concentration in the serum around 3-4 hrs after IL-I2 injection which
corresponded to a complete depletion of cytoplasmic IL-15 (Fig. 13b,c). Serum IL-15
also disappeared rapidly, as the cytokine was undetectable in the serum 24 hrs after IL-12
treatment. Macrophage intracellular IL-I5 which was decreased at 2-3 hours after IL-12
treatment was vastly increased by 18-24 hours after IL-12 injection (Fig 14).

Activated macrophages from tumor animals aid in the initiation of immunoactivation in response to IL-12 treatment.

To determine if the IL-12 induced release of intracellular IL-15 played a
role in IL-12 initiation of a tumor destructive response, anti-IL-15 or an IgG isotype
control was injected into tumor bearing mice 1 hr prior to intra-tumor injection ofIL-12.
Lymphocyte infiltration into the tumor and metastatic lung tissue were then measured 3
and 5 days later by flow cytometry, and the size and integrity of the primary tumor mass
and extent oflung metastasis were assessed 10 days post IL-12 injection. Five days after
IL-12 injection there was a 10 fold increase in infiltrating CD4+ and CD8+ T cells within
the primary tumor. This increase was not observed in mice treated with
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Figure 13. TAMs release IL-15 in vivo in response to IL-12 treatment. a) A blood
sample was collected from normal or tumor bearing mice 3 hrs post IL-12
injection. Serum IL-15 was assayed by ELISA. Data is displayed as mean ± s.d. of 3
mice. p=0.012 for normal versus tumor-bearing IL-12 treated mice. n.d.= none
detected. Results are representative of 2 independent trials (b) Peritoneal M<I>s from
normal (left panel) or tumor bearing (right panel) mice were analyzed for cytoplasmic
IL-15 3hrs after IL-12 injection. Specificity was controlled by pre-labeling with cold
anti-IL-15. c) Mean fluorescence intensity displayed a significant shift in the TAM IL-12
treated group compared to the normal M<I> treated group. Data are displayed as mean ±
s.d. of3 mice per group. Results are representative of2 independent trials.
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anti-IL-IS + IL-12 (Fig. IS). By 10 days post IL-12 injection the tumor volume and
tumor mass were significantly reduced in the IL-12 treated and IL-12 + isotype control
treated groups in comparison to the untreated control group (Fig. 16a). In the IL-12
treated and IL-12 + isotype control treated groups the tumor masses were visibly
ulcerated (Fig. 16b) whereas there was no indication of ulceration in the untreated
controL The volume and mass of the subcutaneous tumor harvested from mice treated
with anti-IL-IS + IL-12 were similar to untreated control group, the anti-IL-IS + IL-12
group did not display visible signs of ulceration (Fig.16b). Furthermore, an H&E stain of
cross sections of the primary tumor mass show both infiltration of lymphocytes and as
well as the breakdown of the tumor stroma in the IL-12 and IL-12 + isotype control
groups, but not in the untreated control or the anti-ILlS + IL-12 treated groups(Fig. 16c).
Similarly, metastatic lungs harvested from mice treated with IL-12 displayed a significant
infiltration of CD4+ and CD8+ T cells and contained dramatically reduced frequency and
size of metastases (Fig. 17). The lungs harvested from mice treated with anti-IL-IS + IL12 displayed very little lymphocytic infiltration and displayed increased frequency and
size of metastatic lesions compared to the group treated with IL-12 alone (Fig. 18).
However, the lungs of anti-IL-IS treated mice did not display as extensive metastatic
tumor growth as the untreated control mice. When these experiments examining IL-12
induced tumor and metastasis destruction were carried out for longer period of time, mice
receiving IL-12 treatment had an 80% survival rate up to 30 days post IL-12 treatment at
which point the untreated control group or animals lacking IL-lS, IL-IS-/- mice or where
release of IL-IS was neutralized in wild type CS7BLl6 mice, had expired.
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Figure 15. Neutralization ofIL-15 reduces T cell infiltration in response to IL-12. Tumor
bearing mice were injected with placebo or IL-12 encapsulated microspheres. One group
was injected with 250 ng anti-IL-15, Ihr prior to IL-12 treatment. The tumor mass was
then harvested and analyzed for infiltrating cells 3 and 5 days after IL-12 injection. Data
are expressed as the mean ± s.d. of 5 mice per group, * p < 0.05 comparing control group
or anti-ILl5 group to IL-12 or IL-12 + isotype control treated groups. Results represent 2
independent trials.
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harvested 10 days post injection for analysis. a) Tumor volume was measured using
bisecting calipers and wet weights were acquired for comparison of the groups. Data are
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digital images, c) H&E stains from tumor cross sections were performed by University of
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In addition to stimulating an anti-tumor immune response, IL-I2 treatment

may also be effective in the break-down of the vascular network supporting the tumor.
Upon examination ofIL-I2 induction of the breakdown of the tumor stroma, we observed
that tumor bearing animals treated with IL-I2 displayed a dramatic reduction in size of
the main blood vessel nourishing the tumor or appeared to be absent in many of the IL-I2
treated mice. However, mice injected with neutralizing anti-IL-IS prior to IL-I2
treatment were comparable to untreated control mice in that the major tumor blood vessel
remained exuberant (Fig. 19).

Macrophages in the tumor microenvironment are activated by cell contact with
tumor cells and tumor exosomes.

IL-I2 treatment induces both production of inflammatory cytokines as well
as release of intracellular IL-IS. However, while IL-I2 can modulate macrophage
function, it can not effectively activate macrophages. Therefore, macrophages that
responded to IL-I2 injection presumably received an activating stimulus from some other
source, e.g.NK cells that were activated in response to the IL-I2 treatment, the
combination of tumor produced cytokines or cell contact with the tumor.
To determine whether NK cells activated by IL-I2 were responsible for
stimulating macrophage activation, macrophages were harvested from beige mice, which
are reported to lack functional NK cells, bearing a subcutaneous tumor or tumor free
mice. Cytokine production and gene expression were then measured by cytokine bead
array (CBA) or qRT-PCR.

Cytokine production TNFa, MCP-I, IL-IO and IL-6
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Figure 19. IL-12 treatment prevents formation or induces the break-down of the major
tumor blood vessel, which is prevented upon neutralization of IL-15. Tumor bearing mice
were i~ected with placebo or IL-12 encapsulated micro spheres. One group was injected
with 250 ng anti-IL-15, Ihr prior to IL-12 treatment. Mice were euthanized 10 days after
IL-12 treatment for analysis of destruction of the tumor and metastasis. Images of the
tumor blood vessel are representative of 5 mice per group.
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were elevated in beige TAMs compared to macrophages from tumor free beige mice upon
LPS stimulation. However, TAM production of IL-6 and TNFa. was further amplified
after 1L-12 injection and IL-IO and MCP-I cytokine production was reduced compared to
placebo treated. Additionally, cytokine genes MIF and TGFp where found to be upregulated in beige TAMs but were significantly reduced upon 1L-12 treatment.
Furthermore, pro-inflammatory IL-15 mRNA was dramatically increased in response to
IL-12 in both normal macrophage and TAMs (Fig. 20). In addition to mRNA expression,
IL-15 protein was measured at ng levels in the serum of tumor bearing beige mice after
treatment with 1L-12, indicating activated NK cells are not essential for activation of
macrophage cytokine production in the initiation phase of the IL-12 induced anti-tumor
response. To confirm that macrophage release oflL-15 in response to 1L-12 treatment
could continue to contributed to the observed CD45+/CD8+ lymphocyte infiltration in
the absence ofNK cells, NK cells were depleted from normal and beige mice by antiNKI.I 24 hrs prior to 1L-12 treatment, additionally to one group neutralizing anti-IL-15
was administered I hr prior to IL-12 injection. Depleting NKI.I + cells did not inhibit
CD8+ T cell infiltration in response to 1L-12 induced IL-15 release. Infiltration was
actually slightly increased in the tumor in the absence ofNK cells (Fig.2I).
The demonstrations that 1) IL-12 does not activate expression of function
in normal resting macrophages, 2) that 1L-12 does induce strong inflammatory functions
in TIMs and TAMs and 3) that NK cells are not essential to the activation ofTIMs and
TAMs, suggests that TIMs and TAMs were activated prior to IL-12 treatment. Several
investigators have reported evidence that TIMs and TAMs are in an activated state and
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Figure 20. Macrophages in beige mice respond to IL-12 treatment. Macrophages were
harvested from the spleen of tumor bearing beige mice before or 3 hours post IL-12
injection. Cells were either a) plated for analysis ofTNFa, MCP-I, IL-IO and IL-6
cytokine production in response to LPS or b) lysed immediately for mRNA extraction to
assay cytokine gene expression by qrt-PCR. c) A blood sample was also taken to
measure serum IL-15 levels by ELISA. Results are displayed as mean ± s.d. of 3 mice.
Cytokines TNFa, MCP-l, IL-IO and IL-6 are from a single trial of3 separate mice, Gene
expression ofMIF, TGF(3, and IL-15 are representative of3 independent trials of3
separate mice, and serum IL-15 levels are representative of 2 independent trials of 3
separate mice.

-50-

Figure 21. Depleting NK cells does not inhibit T cell infiltration in response to IL-12
induced IL-15 release. Tumor bearing beige (a,c) or tumor bearing wild type (b,d) were
depleted ofNK cells by injection of anti-NKl.l 24 hrs prior to IL-12 treatment. Anti-IL15 was injected 1 hr prior to IL-12 injection. The tumors (a,b) and lungs (c,d) were
harvested 5 days after IL-12 treatment to analyze infiltrating CD8+ T cells. Percentages
displayed are based on percent of CD45+. Results are representative of 2 independent
trials of 4 mice per group.
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express functions which promote angiogenesis and tumor growth. The mechanism of
this activation, especially of the tumor-distal TAMs remains unresolved 26,31,32,35,36,48. To
corroborate that macrophages were in as activated state in vivo in the 3LLC model, TIMs
and TAMs were purified from the primary tumor mass, or from the spleen, peritoneal
cavity, and lung tissue of mice bearing subcutaneous 3LLC tumors and lung metastasis.
The macrophages were plated for 17 hrs without exogenous stimulation after which the
cultures were assayed for cytokine accumulation. TAMs from the spleen, peritoneal
lavage, and the lung produced 2-16 times more TNFa, MCP-1, IL-lO, and IL-6 than
macrophages from normal healthy tissues. TIMs also produced elevated levels of TNF a,
MCP-1, and IL-6 but did not produce detectable levels ofIL-lO (Fig.22a). These results
were confirmed in other lung carcinoma models, LL2 and TC-1, indicating that
macrophages are activated in the presence of a tumor and the results observed were not
unique to the 3LLC carcinoma (Fig.22b).
To determine whether cytokines or other soluble factors released by the
tumor were responsible for macrophage activation in situ, macrophages from normal
mice were cultured in vitro with the filtered supernatant from primary 3LLC tumor cell
cultures. The 3LLC supernatant contained high levels ofMCP-1, VEGF, and TGFp.
Cytokine analysis did not reveal evidence of macrophage activation with the exception of
pro-MMP-9, which has been shown to be released in response to high levels ofVEGF 35,
37.

However, culturing the macrophages in unfiltered tumor supernatant clearly resulted

in activation as measured by an increase in production ofTNFa, MCP-1, IL-lO, IL-6,
VEGF, and pro-MMP-9 (Fig.23). Previous reports have identified tumor released
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Figure 22 - TAMs are actively producing cytokines upon ex vivo analysis. M<l> were
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mice bearing a 0.6cc tumor with lung metastasis .. (a) TIMs and TAMs were plated
overnight with no further stimulation for 17 hours to allow for cytokine accumulation.
Supernatants were then harvested and a')sayed by CBA. (b) TAMs from various tumor
models were harvested and assayed for cytokine production. Data represented as mean +
s.d., n = 3 mice.

* p < 0.0001 comparing TAMs vs macrophages from control animals.
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exosomes of the tumor membrane expressing tumor cell surface molecules 54. The
exosomes are thought to contribute to the systemic suppression of the immune system as
well as in tumor metastatic development 54,55,90,91.

This led us to consider the possibility

that exosomes in the unfiltered tumor culture supernatant could activate macrophages
upon cell contact. To determine whether exosomes released by the tumor were capable
of activating macrophages, exosomes were purified by magnetic bead selection using a
tumor specific hMuc-l Ab and were cultured with macrophages for 17 hrs. ELISA and
CBA analysis confirmed that normal peritoneal macrophages cultured with exosomes
produced elevated levels of1NFu, MCP-l, IL-lO, IL-6, VEGF, and pro-MMP-9 (Fig.24).

Tumor cell and macrophage interactions occur through CD40/CD154 and
NKG2DlRae-1.

Previous studies on many types of cancer reported that tumor cells
express activation receptors and their corresponding ligands such as CD40 ICD 154 and
NKG2DlRae-1

20,53,56,92,93.

We have confirmed that these ligands are expressed by

3LLC ex vivo (Fig 25). Macrophages are known to be activated by ligation ofCD40
and macrophages purified from tumor bearing mice displayed elevated expression of
CD40 compared to macrophages from tumor-free mice (Fig.25). Analysis of
macrophage surface expression ofNKG2D produced varying results when assayed by
flow cytometry, 3 trials indicated elevated NKG2D surface expression on peritoneal
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Figure 25. Tumor cells express CD40L and Rae-I and TAMs but not normal M<l>
express elevated levels of surface CD40 and NKG2D receptors. 3LLC as determined by
hMuc-l + population were stained ex vivo for cell surface expression with fluorescent
Abs to CD40L (CDl54) and Rae-I. M<l>s as determined by the Mac-l + (CDIlb)
population were stained ex vivo for cell surface expression of CD40 and NKG2D.
Staining for NKI.I was used as a control to verify populations were free ofNK
contamination. Results are representative of 3 independent trials.
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TAMs in comparison to nonnal peritoneal macrophages, while 2 trials displayed only
background staining levels. The data was even more disconcerting by the observation
that both TAM and nonnal macrophages from lung tissue stained positive for NKG2D
surface expression, by others in our lab (data not shown). However the presence of
NKG2D mRNA was observed in both TAM and nonnal macrophages by qrt-PCR,
NKG2D gene expression was observed to be up-regulated by a factor of 78 in peritoneal
TAMs in comparison to nonnal peritoneal macrophages and up-regulated by a factor of
32 compared to nonnal resting NK cells purified from a spleen of a healthy animal
(Fig.26). Interestingly, nonnal peritoneal macrophages cultured for 24 hrs in the
presence of3LLC exosomes and culture supernatant displayed increased NKG2D gene
expression in comparison to nonnal macrophages cultured without exosomes (Fig. 26).
To detennine whether 3LLC exosomes were activating macrophages by ligation of CD40
or NKG2D, nonnal peritoneal macrophages were stimulated with 3LLC exosomes in the
presence or absence of blocking anti-CD I 54 and/or anti-NKG2D. Blocking either
CDl54 or NKG2D significantly reduced exosome induced TNFu, IL-lO, IL-6, and proMMP-9 production. Blocking both NKG2D and CD40 ligation completely abrogated
cytokine release including MCP-l, which was not significantly affected by blocking only
one receptor ligand interaction (Fig 27). A titration of the Abs shows a dose dependant
response when added separately, but total blockage of cytokine production or release
when added in combination (Fig. 28). To insure specific blocking by anti-NKG2D,
rmNKG2D-Fc was added to the cultures. The addition ofrmNKG2D-Fc prevented
inhibition of cytokine production by anti-NKG2D (Fig 29). Further analysis revealed
that, wild type and
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Figure 26. TAMs express elevated NKG2D gene expression. Macrophages were
harvested from normal or tumor bearing mice and lysed for mRNA extract immediately
or normal macrophages were plated with exosomes for 24 hrs prior to lysis. NK cells
were harvested from the spleen of a normal mouse and used as a positive control for
NKG2D expression. 3LLC tumor cells were also lysed ex vivo for comparison. Results
are representative of 4 independent trials.
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Figure 27. CD40 and NKG2D are involved in macrophage activation by tumor
exosomes. Macrophages were purified from the peritoneal lavage of normal animals and
cultured for 17 hrs with 3LLC exosomes in the presence or absence of blocking Abs to
NKG2D and CD 154. The supernatants were then harvested and analyzed for cytokine
production by CBA and ELISA. Results are displayed as mean ± s.d. of triplicate
cultures. *p<0.05 comparing un-stimulated vs exosome stimulated and exosome
stimulated vs exosome stimulated in the presence of blocking Abs. Results are
representative of 3 independent trials.
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Figure 28. Blockade of either NKG2D or CD40 ligation interferes with exosome
activation ofMF. The combined inhibition of ligation of both CD40 and NKG2D was
synergistic and completely abrogated the response ofMF to 3LLC exosomes. Normal
peritoneal M<D were plated in the presence or absence of3LLC exosomes in increasing
concentrations of anti-NKG2D and/or anti-CD 154 Ab separately or in combination for 17
hrs. Culture supernatants were then harvested and analyzed by ELISA for cytokine
production. Results are displayed as mean ± s.d. of triplicate cultures and representative
of two independent trials.
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Figure 29. Anti-NKG2D Ab specifically blocks macrophage activation by exosome
NKG2D ligation as shown Fc-rmNKG2D inhibited the ability of the blocking antibody to
prevent cytokine production. Peritoneal macrophages were purified from (a) normal
animals or (b) tumor bearing animals and cultured for 17 hrs with 3LLC exosomes in the
presence or absence of blocking anti-NKG2D or Fc-rmNKG2D + anti-NKG2D. The
supernatants were then harvested and assayed by ELISA. Data are displayed as mean ±
s.d. of triplicate cultures. The results are representative of 2 independent trials.
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CD40-/- macrophages cultured with exosomes for 17 hrs were activated as measured by
macrophage cytokine production. CD40-/- macrophages stimulated with exosomes were
observed to produce substantial levels ofMCP-I, IL-6, and pro-MMP-9 production in
comparison to un-stimulated macrophages, but they produced significantly less TNFu,
MCP-l, IL-I 0, IL-6, and pro-MMP-9 than wild type macrophages stimulated with
exosomes (Fig.30). In addition blocking NKG2D in CD40-/- macrophages completely
abrogated TNFu, MCP-I, IL-I 0, IL-6,and pro-MMP-9 production and/or release (Fig.
30). As a control it was shown that blocking Abs for NKG2D and CD154 did not prevent
macrophage activation of cytokine production in response to LPS stimulation (Fig 31).

CD40 is essential for metastatic growth.

Macrophages have been shown to be important for tumor metastatic
capabilities. They have been referred to as the mediators of the angiogenic switch in
tumorigenesis by providing many cytokines and growth factors important for tumor
escape and metastasis, particularly VEGF and MMP-9

26,30,37,94.

Therefore to determine

whether the failure of macrophage activation by CD40 ligation in vivo altered the
activities of TAMs or tumor cells, 3LLC tumor cells were injected subcutaneously into
wild type or CD40-/- mice and macrophages were harvested when the tumors were
approaching 0.5cc to assay for cytokine production. Production ofTNFu, MCP-l, IL-lO,
and IL-6 were greatly decreased in the TAMs from CD40-/- animals compared to wild
type TAMs (Fig.32). Interestingly, even the release of intracellular IL-15 upon exosome
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Figure 30. CD40 and NKG2D are involved in macrophage activation by tumor
exosomes. Peritoneal M<l>s from normal or CD40-/- mice were cultured overnight with
3LLC exosomes in the presence or absence of neutralizing anti-NKG2D. The culture
supernatants were assayed for cytokines by CBA and ELISA for MMP-9. Data are
expressed as mean ± s.d. of triplicate cultures * p <0.05 comparing groups WT M<l>s vs
CD40-/- M<l>s stimulated by 3LLC exosomes. Data representative of 2 independent
trials.
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Figure 31. Blocking Abs to NKG2D and CD 154 do not inhibit macrophage cytokine
production in response to LPS stimulation. Macrophages were purified by bead selection
from peritoneal lavage of normal mice. Cells were then stimulated with LPS or 3LLC
exosomes in the presence or absence ofanti-NKG2D and anti-CD154 blocking Abs for
17 hrs. The supernatants were then harvested and assayed by ELISA to detect cytokine
production. Results are displayed as mean ± s.d. of triplicate cultures. Results are
representative of 2 independent trials.

-65-

WTcontrol
CD40-/- control
WTTAMs
CD40-/- TAMs

*

*
0

500
1000 1500 2000 0
pg/ml TNFa

0

100

4

2
3
ng/ml MCP-I

WTcontrol
CD40-/- control
WTTAMs
CD40-/- TAMs

*

*
200

300

400 500 0

pg/mIIL-IO

2

3
4
ng/mIIL-6

5

6

Figure 32. Cytokine secretion is decreased in TAMs from CD40-/- tumor bearing mice.
Peritoneal M<l>s were purified from peritoneal lavage of wild type and CD40-/- tumor
bearing mice and cultured overnight without stimulus to allow for cytokine accumulation.
The supernatants were analyzed for cytokines by CBA. Data are expressed as mean ± s.d.
for 3 mice per group. *p<O.05 comparing groups wild type TAMs vs CD40-/- TAMs.
Results are representative of 2 independent trials.
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Figure 33. Tumor activated macrophage IL-15 release is blocked in the absence ofCD40
and/or NKG2D ligation. Wild type or CD40 -/- peritoneal macrophages were cultured for
2 hrs with exosomes + 5nglml IL-12 in the presence or absence ofanti-NKG2D. IL-15
was assayed by ELISA. Data represented as mean + s.d. n = 3 mice, p= 0.001 for
anti-NKG2D vs. wild type control, p = 0.0008 for CD40-/- vs. wild type control, and
p = 0.0001 for CD40-/- + anti-NKG2D vs. wild type control. n.d. = no cytokine detected.
Data representative of 2 independent trials.
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and IL-12 stimulation was blocked in the absence of functional CD40 or upon the
addition of anti-NKG2D blocking Ab (Fig. 33). Conversely, although cytokine
production and release by TAMs was inhibited in CD40-/- mice, growth of the primary
tumor mass appeared to be more rapid. However, further observations revealed that
unlike wild type animals there were no metastatic lesions in the lung tissue ofCD40-/mice (Fig. 34), coinciding with a significant decrease in pro-MMP-9 and VEGF
production by TAMs from CD40-/- animals (Fig. 35).

TAMs stimulate tumor cells via CD40/CD154 interaction.

The reduction in cytokine production was observed not only in the CD40/- TAMs, but was also significantly decreased in tumor cells harvested from CD40-/animals in comparison to wild type mice (Fig.36). To determine whether this effect was
due at least in part to reduced interaction with macrophages, the stability of tumor
phenotype, which contributes to macrophage activation, was examined by flow
cytometry. We observe that, 3LLC phenotype is not constitutive, but when cultured in
vitro in the absence of the tumor stroma as well as the absence of macrophages or
macrophage produced tumor supportive cytokines, the expression of surface receptors
and ligands recedes (Fig.37a and Table I). However, adding TAMs, but not normal
macrophages, to cultures sustained or restored tumor expression of surface molecules,
CD40, CDI54,NKG2D, CD44, IL-15RP, Rae-I, and H2Kb (Fig.37b and Table I). TAM
support of tumor phenotype appeared to be dependent on several receptor ligand
interactions, as indicated by the observation that TAMs from CD40-/- only were able to

-68-

CD40-/-

Wild type

Wild type

CD40-/-

Figure 34. CD40-/- tumor bearing animals displayed reduced lung metastasis in
comparison to tumor bearing wild type mice. Mice bearing O.5cc subcutaneous tumors
were sacrificed and purfused for lung extraction. The lungs were then sent to the
University of Louisville Pathology Dept. for sectioning and an H&E staining. Cross
sections were then scanned and digital pictures were taken at lOx magnification. Images
are representative of 3 mice per group.
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Figure 35. CD40-/- TAMs produce reduced levels ofMMP-9 and VEGF in comparison
to wild type TAMs. Peritoneal M<1>s were purified from peritoneal lavage of wild type
and CD40-/- tumor bearing mice. The cells were then cultured overnight without
stimulus to allow for ELISA. Data are expressed as mean ± s.d. for 3 mice per group.

*p<0.05 comparing groups wild type TAMs vs CD40-/- TAMs. Results are
representative of 2 independent trials.
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Figure 36. Tumors grown in CD40-/- mice produce significant amounts of angiogenic
factors MMP-9 and VEGF, although drastically less than tumors grown in wild type
mice. Tumors approaching O.5cc were harvested from wild type or CD40-/- mice, made
into single cell suspension and 3LLCs were purified by hMuc-l Ab and magnetic beads.
The cells were then plated for 17 hours to allow for cytokine accumulation without
stimulus. The supernatants were then assayed by ELISA. Data are displayed as mean ±
s.d. of triplicate cultures from 3 separate mice. *p<O.05 comparing tumors from WT mice
to tumor cells from CD40-/- mice.
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Figure 3 7 - TAMs restore tumor expression of surface molecules. Tumors were harvested
and stained for the presence of CD 154, CD40, IL-15Rb and Rae-l ex vivo, after 3 in vitro
passages and after 3 in vitro passages with TAMs added for the last 24 hrs. Results are
representative of 4 independent trials.
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Table 1. Tumor - macrophage interactions dependent on many receptor ligand
interactions, wild type TAMs, but not CD40-/- or IL-IS-/- TAMs restore various tumors
phenotype. Tumors were harvested and stained for the presence of CD40, CD1S4, CD44,
Rae-I, NKG2D, IL-1SRb, and H2Kb ex vivo, after 2 in vitro passages and after 2 in vitro
passages with TAMs from WT, CD40-/- and IL-IS-/- mice added for the last 24 hrs. Data
are displayed as mean fluorescence intensities (MFls). Results are representative of2
independent trials.
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restore 3LLC expression of CD44 and Rae-l but were not able to restore 3LLC expression
of CD40, CD154, NKG2D,

IL-15R~,

or H2Kb. In contrast, TAMs from IL- 15-/- mice

effectively restored expression ofCD44, NKG2D, and H2Kb, but not CD40, CD154, Rae1 or IL-15R~. In addition to surface molecule expression 3LLC cytokine production and
gene expression was also greatly reduced with each in vitro passage (Fig.38). However,
cytokine production and gene expression was restored or in some instances increased
when 3LLCs and TAMs were co-cultured overnight (Fig 38). This apparent symbiotic
relationship between TAMs and tumor cells held true for other carcinoma cell lines, such
as LL-2 and TC-l and to a smaller degree the Bl6FI melanoma (Fig. 38).
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Figure 38. Tumor cytokine production induced by TAMs. Tumors were harvested and
lysed for mRNA extraction for qr-PCR analysis ex vivo, after 3 in vitro passages and after
3 in vitro passages with TAMs added for the last 24 hrs, the cells were then separated prior
to lysis by magnetic beads. Data are displayed as ngll 06 cell mRNA and mean ± s.d. of
triplicate cultures and 3 individual mice. *p<0.05 comparing ex vivo tumor cells vs in
vitro passaged tumor cells or passaged tumor cells vs passaged tumor cells + TAMs.
Results are representative of 3 independent trials. Results were confirmed in TC-l
carcinoma and B 16F 1 melanoma.
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DISCUSSION

Macrophages display an array of diverse functions which are differentially
expressed based on response modifiers present in the environment. TAM function is a
prime example of functional plasticity, as tumor produced metabolites alter macrophage
functional properties toward tumor supportive. Tumor cells employ a number of
mechanisms to prevent detection and destruction by the immune system. Mechanisms
including, the down regulation of HLA class I expression on their surface, the absence of
co-stimulatory molecules on tumor cells, which reduces the ability of the adaptive immune
response to detect the tumor, and the production of cytokines and growth factors, which
further promotes an anti-inflammatory environment

19,20,28,42, 53,95,96.

These mechanisms

can directly act on cells of the immune system by preventing their activation, for example,
Ag processing is decreased on class I and class II MHC, NK cytotoxic activity, IFNy
production and NKG2D expression are down regulated, and there is a significant increase
in the number of regulatory T cells 28,67,97,98. The tumor and the suppressive tumor
environment contributes to the altered functional phenotype and activities of macrophages
1,5,45,96.

Macrophages within the tumor contribute to tumor growth by the production of

pro-tumorigenic factors as shown in figure 7 and macrophages distal to the tumor mass
also produce pro-tumorigenic cytokines and growth factors as shown in figures 5, 7, 11,
and 12. Tumor infiltrating and tumor associated macrophages, as shown here, are
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modulated by tumor produced cytokines, but are likely to receive the activation stimulus
by cell contact with tumor cells or tumor exosomes.
Exosomes can bind to cells and mediate different biological functions.
They were first observed to be biologically active in 1996 when B cell derived exosomes
were shown to induce Ag specific MHC class II restricted T cell responses and also in
1998 in a report where DC derived exosomes were shown to induce tumor eradication 99101 _

There is evidence of interaction between tumor derived exosomes and APCs. In

addition to ligands, most tumor derived exosomes also have enriched heat shock proteins
(HSPs), which are believed to increase interaction or uptake by APCs 50,51. The exosome /
APC interaction was shown to induce stimulation of an immune response, mice were
injected with a single dose of plasmocytoma cell derived exosomes, and were then
challenged by injection of wild type tumors. The mice undergoing challenge generated
specific cytotoxic T cells with tumor specific immunity and were protected from tumor
development 50-52.
The functions that an exosome can mediate will be highly dependent on
the surface proteins expressed. The surface complexes of exosomes include ligands to
various cell surface receptors, which can mediate interactions between two cells. In the
case of the 3LLC model used in this study, tumor cells and tumor exosomes were observed
to be able to activate macrophages by ligation of CD40 and/or NKG2D as evidenced by 1)
the activation of macrophages from culture with tumor released exosomes, shown in
figures 21 and 22" 2) the inhibition of activation, shown in figures 25 and 26, by antiCD154 and/or anti-NKG2D, and 3) by the attenuated activation stimulation of ex vivo
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TIMs and TAMs from tumor bearing CD40-/- mice along with the reduced responsiveness
of CD40-/- macrophages stimulated with exosomes as shown in figures 27 and 28.
Taking a closer look at the impact ofCD40 deficiency on tumor growth and
macrophage activation, we observed a vast difference in the activation of both TAMs and
tumor cells from CD40-/- tumor bearing mice. TAMs from these animals produced
significantly less cytokines than TAMs harvested from wild type mice bearing tumors
which were comparable in size to the CD40-/- mice. In addition to reduced macrophage
activation and cytokine production, CD40-/- tumor bearing mice, were not observed to
have metastatic lesions on the lung, whereas the lungs of tumor bearing wild type mice
contained areas of heavy metastases. Application of information from reports
demonstrating that macrophages are important for metastatic spread 7,20,31, and the data
herein, which demonstrates that TAMs are not activated in CD40-/- tumor bearing mice,
and that normal macrophages are not activated by exosomes in the presence of blocking
anti-CD 154, indicates that there is link between macrophage activation by CD40 ligation
and tumor progression and the development of metastasis. This connection could
potentially serve as a target for CD40 driven therapies. Administering an agent such as
CD154 or anti-CD40 rnAb may disrupt the tumor-macrophage relationship or the
activation of tumor supportive activities in macrophages by interfering with the
availability of cell contact interactions through CD40-CDI54. In speculation, the
disruption of this relationship may relieve some of the effects of the irnrnuno suppressive
environment on NK, DC and T cells, enabling mobilization of an anti-tumor response.
Targeting CD40, by treatment with ligands and/or monoclonal Abs has previously been
attempted, in the aspect of its direct effect on the tumoi9 ,33, 110. The relevance of CD40
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expression by tumors is unclear. However, literature indicates that CD40 stimulation on
tumor cells, results in increased cytokine production by the tumor, most commonly IL-6
and IL-8 93,114,118. Both of these cytokines are important for angiogenesis and contribute
to metastatic spread. CD40 activation has been shown to both induce proliferation and
survival in many tumors, malignancies, and leukemias by inhibiting Fas mediated
apoptosis, and has also been reported to induce growth arrest and apoptosis in several
other carcinomas although, through unknown mechanisms 29, 112, 114-117. The observed
differences in stimulation of tumor cells by CD40 ligation have been attributed to the
setting in which stimulus was received, for example, prolonged vs. transient stimulation
and/or soluble CD 154 vs. membrane bound stimulation 29,33,93. The activation of CD40
has been examined in therapeutic settings by the delivery of soluble CD 154 or anti-CD40
mAb and/or delivery ofligand through gene therapy. Reports suggest that CD154 therapy
has shown promising effects, inducing elevated levels of serum IFNy and IL-12 as well as
inducing a measurable increase in T cell activation, which can specifically recognize and
destroy tumor cells 33,110,114-116,119. The greatest successes acquiring DC and CD8+ T cell
responses were attained by combining CD40 ligation with the administration of proinflammatory cytokines IL-12 or IL-2. CD40 stimulation can synergize with IL-2 for antitumor responses, as was shown against mouse metastatic renal cell carcinomas, the
administration of combined treatment resulted in increase numbers of tumor-specific
CD8+ T-cells and dendritic cells in both the spleen and liver

6,29, 120, 121.

In addition to CD40 ligation, in this study, we demonstrate a potential role for
NKG2D ligation in tumor macrophage activation. NKG2D is an activation receptor,
typically reported to be preferentially expressed by NK cells and functions, when
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activated, to allow for the detection and destruction of diseased host cells 53. Furthennore,
it is a multi subunit receptor complex, and NKG2D signaling is mediated by specialized
signaling adaptors. Mouse NKG2D can associate with two distinct adaptors, DAP-IO and
DAP-12, while human NKG2D only associates with DAP-lO 92. NKG2D receptor is
constitutively expressed on most innate immune effector cells including NK, TCRy3 T
cells and most NKT cells. NKG2D expression on macrophages is controversial, it was
first reported by Diefenbach in 2000, but the reports of surface expression have not been
able to be confinned, although, mRNA expression has been reported several times 20,92,122.
Interestingly, many reports show that there is functional NKG2D on murine IFN producing
dendritic cells, which are of myeloid origin 20,92, 123, 124. We demonstrate here that levels of
NKG2D mRNA gene expression can be up or down regulated in macrophages. High
NKG2D gene expression is observed in TAM populations and lower expression is
observed in nonnal macrophages populations, which can also be up-regulated when
nonnal macrophages are cultured in the presence of3LLC exosomes. This data is in
opposition to patterns ofNKG2D expression in NK cells. Nonnal NK cells express high
levels ofNKG2D, whereas NK cells from tumor animals express lower levels ofNKG2D,
both mRNA as well as protein expression. Ligation ofNKG2D results in surface
modulation of the receptor and reduced function upon subsequent receptor engagement.
Thus, chronic exposure to tumor cells expressing ligands to NKG2D alters NKG2D
signaling in NK cells which facilitates the evasion of tumor cells from NK detection and
cytotoxic activities 53.
Another avenue for therapy currently under investigation is cytokine therapy.
Rather than targeting activation of receptors, our data supports the idea that it may be more
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beneficial to use the activation provided by the tumor and modulate the functions
expressed by immune cells through cytokine treatments. TIMs and TAMs appear to be
both activated and modulated by tumor cells and tumor exosomes, but they maintain a
high degree of plasticity, they therefore, can continue to be rapidly converted to other
functional phenotypes by the appropriate cytokine treatment. As we have shown here,
TIMs and TAMs are observed to be producing tumor supportive cytokines, TGFp, VEGF,
MIF, MCP-l, and IL-I0, upon ex vivo analysis. However, IL-12 treatment in vitro and in
vivo rapidly down-regulated or attenuated production of the tumor supportive cytokines
and concomitantly up-regulated production of pro-immunogenic cytokines, TNFa, IL-6,
IL-18, and released their store of cytoplasmic IL-15. The rapid change in the functional
profile suggests three things, 1) IL-12 treatment can effectively overcome the influence of
the tumor environment and allows the shift of macrophage functions form pro-tumorigenic
to pro-immunogenic, 2) the shift in macrophage function occurs very rapidly, at least
within 90 min of IL-12 treatment, and is stable for at least up to 5 days, and 3) the shift in
TAM phenotype occurred systemically as was observed by analysis of tumor infiltrating,
peritoneal, lung and splenic macrophages. The importance of this shift in function, is that
1) macrophages no longer contribute to angiogenesis and tumor growth and 2) it allows for
a reduction in the immunosuppressive environment, allowing NK and T cells to become
activated. NK cells have been observed to become activated 3-5 days after IL-12
treatment and CD8+ CTLs have been observed to be present and activated 5-7 days post
IL-12 treatment, both of which display cytotoxic activities and producing elevated levels
of pro-inflammatory cytokines 61,62, 102-104. The activation and pro-inflammatory cytokine
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production ofNK and CTLs, then drives the anti-tumor response, including the induction
of cytotoxic and effector activities by the macrophage.
IL-12 has a strong anti-tumor effect against many cancers including melanomas
and colon, renal, mammary and ovarian carcinomas

13,60,64.

However, enthusiasm for the

use ofIL-12 as a treatment for human patients, waned when i.v. administration led to
severe toxicity in phase II trials

95.

However, toxicity has been greatly over come in recent

trials by administering the cytokine by subcutaneous injections or most impressively by
local delivery to the tumor in encapsulated microspheres, which allows for a slower and
prolonged release ofIL-12

23,61,103,105.

A single dose ofIL-12 has been shown to cause

elevated levels of IFNy, IL-18, and IL-15

63,96,106.

Tumor regression was consistent when

elevated serum levels of IFNy, IL-18, and IL-15 were maintained. While it has been
established that NK and T cells respond to IL-12 by increasing production of IFNy, they
do not produce or release IL-15. Many cells, such as epithelia and other stromal cells,
reportedly express IL-15 on their membrane, the source of IL-12 induced free IL-15 in the
serum is unknown. We show here that TAMs rapidly release cytoplasmic IL-15 as a
bolus, during the peak time point at which IL-15 is observed in the serum, going from
undetectable to 5-6 ng/ml. This data demonstrates that TAMs are responsible, at least in
part, for elevated serum IL-15.
The rapid release of IL-15 from macrophages as well as other stromal cells
in response to IL-12 treatment seems to playa significant role in the efficacy of IL-12
treatment, as evidenced by the lack of lymphocyte infiltration into the tumor and
metastatic lung, as well as the lack of tumor destruction and metastatic clearance when IL15 is neutralized or blocked. The data shown in this study, in the reports ofIL-15 being
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essential to NK survival and activation 76, the demonstration of the essential role ofIL-15
in the rescue of anergic CD8+ T cells within the suppressive tumor environment 45,75,81,107,
108

and the observation ofthe ability ofIL-15 to reverse tumor induced inhibition of class I

MHC processing by DCs indicates that IL-15 is an essential component for effective
cytokine therapy 58,71,72,74,109.

IL-15 is currently being examined as a potential candidate

for cancer therapies 69, however, IL-15 alone has not been shown to be as efficient as it is
in combined cytokine therapies 32,61. Our study indicates that TAM release ofIL-15 in
response to IL-12 is substantial and important to the initiation and promotion of the antitumor response. It is likely that upon release, IL-15 combines, or acts synergistically,
with the IL-12, as well as other released pro-inflammatory cytokines such as IL-18, IL-21,
IFNy, etc. to promote the innate and adaptive anti-tumor responses 61,70,84.
According to literature there seems to be a link between available IL-15 and
NKG2D expression. IL-15 has been reported to up-regulate both DAP-lO and NKG2D
expression, as well as prime NKG2D signal transduction by constitutive ERK
phosphorylation 92, 125-127. However, the mechanism ofthis priming remains elusive.
Interestingly we observe that macrophage release of IL-15 is inhibited when NKG2D is
blocked, which further indicates there may be a link between IL-15 and NKG2D
expression. Smyth et. al. report that neutralization ofNKG2D reversed the efficacy ofIL12 treatment 92, 128. This report agrees with our data in two ways, 1) we show that
neutralization ofNKG2D prevents IL-15 release, and blocking IL-15 prevents lymphocyte
infiltration into the tumor and lung, and prevents tumor destruction and metastatic
clearance, and 2) neutralizing NKG2D attenuated production of other pro-inflammatory
cytokines by macrophages, important for both the initiation and effector phases of the anti-
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tumor response. It is the hope that future investigations into the macrophage-tumor cell
relationship will lead to better understanding of TAM activation and TAM support of
tumor phenotype. Understanding of this relationship is likely to provide insight as to the
mechanisms by which IL-12 induces IL-15 release by TAMs, which currently remains
elusive, but is clearly an important event for effective cytokine therapy.

Conclusions

This study provides insight as to the activation and modulation of TAMs
by tumor cells, tumor exosomes and tumor produced cytokines. We demonstrate that
TAMs are not a stable, functional subset of suppressive tumor macrophages, but can
rather can be rapidly converted to display pro-immunogenic functions by the appropriate
pro-inflammatory cytokine treatment both in vitro and in vivo. Furthermore, in this
demonstration we observed that macrophages are responsible, in part, for the initiation
of an anti-tumor immune response by releasing a bolus of IL-15 upon treatment with IL12. IL-15 is important to the mobilization of the NK, CD4+, and CD8+ T cells, as we
demonstrated by the inhibition of mobilization when IL-15 was blocked during IL-12
treatment. As an indication of their importance in initiation of anti-tumor responses
macrophages are capable of responding to IL-12 treatment, decreasing pro-tumorigenic
cytokine production and increasing pro-immunogenic cytokine production and releasing
intracellular IL-15, in the absence ofNK cells. These functions occurred at the same rate
and level whether NK cells were present or absent providing further evidence that TAMs
are in an activated state, having been previously activated by the tumor, and modulate
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their function upon lL-12 treatment. Based on this study we hypothesize that it is these
mechanisms by which lL-12 is an effective treatment agent. Regardless of the therapy, it
seems to first be necessary to disrupt the immuno subversive activities of the tumor,
including the disruption of the tumor / macrophage relationship. This disruption
provides the needed window of opportunity which allows for the generation of an antitumor cytotoxic response, and which could possibly lead to the development of central
memory for long term tumor immunity.
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